Ribomic Inc.
Notice on Change in Dosing Regimen (1 mg/kg Once Weekly) and Safety in Domestic Phase II Long-Term Dosing Trial
In the domestic Phase II long-term dosing trial, the first subjects who transitioned to 1 mg/kg once-weekly dosing showed no new safety concerns up to three months after transition, and long-term safety data will be supplemented to the WAKABA trial. Impact on full-year results for the fiscal year ending March 2027 is unclear; the document states there is no impact.
Key Figures
- Number of subjects evaluated for safety: Unknown (document notes 11 of 12 subjects are participating)
- Safety concerns at three months after transition: None
- Transition to WAKABA trial dosing regimen: First subject reached three months after transition
AI要約
Key Points
This is a status report on the domestic Phase II long-term dosing trial for umbedaptanib pegol (RBM-007) in achondroplasia. It discloses that among subjects with more than one year of long-term dosing who transitioned to the same dosing regimen as the WAKABA trial (1 mg/kg subcutaneous once weekly), no new safety concerns were observed up to three months after transition. Currently, 11 of 12 subjects are participating in the trial, and 7 subjects remain ongoing. Follow-up results for the first subject who transitioned have been reported. The company states there is no impact on full-year results for the fiscal year ending March 2027.
Impact on Investors and Outlook
Accumulation of safety data from the long-term dosing trial and the WAKABA trial could complement safety information and potentially expand treatment options. However, the current financial impact is unknown, and future trial progress and approval status could still affect performance.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
